BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 27425654)

  • 1. Discovery of Novel Polo-Like Kinase 1 Polo-Box Domain Inhibitors to Induce Mitotic Arrest in Tumor Cells.
    Qin T; Chen F; Zhuo X; Guo X; Yun T; Liu Y; Zhang C; Lai L
    J Med Chem; 2016 Aug; 59(15):7089-96. PubMed ID: 27425654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
    Shan HM; Shi Y; Quan J
    ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
    Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB; Woo SU; Yim H
    J Cell Physiol; 2015 Dec; 230(12):3057-67. PubMed ID: 25975351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
    Berg A; Berg T
    Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells.
    Scharow A; Raab M; Saxena K; Sreeramulu S; Kudlinzki D; Gande S; Dötsch C; Kurunci-Csacsko E; Klaeger S; Kuster B; Schwalbe H; Strebhardt K; Berg T
    ACS Chem Biol; 2015 Nov; 10(11):2570-9. PubMed ID: 26279064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
    Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
    Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells.
    Chapagai D; Ramamoorthy G; Varghese J; Nurmemmedov E; McInnes C; Wyatt MD
    J Med Chem; 2021 Jul; 64(14):9916-9925. PubMed ID: 34210138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE.
    Craig SN; Baxter M; Chapagai D; Stafford JM; Nurmemmedov E; Altomare D; Wyatt MD; McInnes C
    Eur J Med Chem; 2022 Jan; 227():113926. PubMed ID: 34735919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.
    Park JE; Kim TS; Kim BY; Lee KS
    Cell Cycle; 2015; 14(22):3624-34. PubMed ID: 26513691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
    Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
    Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of naphthalimide-derivatives as novel PBD-targeted polo-like kinase 1 inhibitors with efficacy in drug-resistant lung cancer cells.
    Li P; Li Y; Ma X; Li L; Zeng S; Peng Y; Liang H; Zhang G
    Eur J Med Chem; 2024 May; 271():116416. PubMed ID: 38657480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Degradation of Polo-like Kinase 1 by a Hydrophobically Tagged Inhibitor of the Polo-Box Domain.
    Rubner S; Scharow A; Schubert S; Berg T
    Angew Chem Int Ed Engl; 2018 Dec; 57(52):17043-17047. PubMed ID: 30351497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
    Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
    PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of nitroimidazole-oxime derivatives targeting the polo-box domain of polo-like kinase 1.
    Sun J; Liu HY; Xu RF; Zhu HL
    Bioorg Med Chem; 2017 Dec; 25(24):6581-6588. PubMed ID: 29100732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
    Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
    Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of acylthiourea derivatives as potent Plk1 PBD inhibitors.
    Yun T; Qin T; Liu Y; Lai L
    Eur J Med Chem; 2016 Nov; 124():229-236. PubMed ID: 27592392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designed inhibitor for nuclear localization signal of polo-like kinase 1 induces mitotic arrest.
    Chen F; Zhuo X; Qin T; Guo X; Zhang C; Lai L
    Chem Biol Drug Des; 2017 May; 89(5):732-740. PubMed ID: 27882722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Based Virtual Screening and Biological Evaluation of Peptide Inhibitors for Polo-Box Domain.
    Yan F; Liu G; Chen T; Fu X; Niu MM
    Molecules; 2019 Dec; 25(1):. PubMed ID: 31892137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and evaluation of d-amino acid-containing peptidomimetics targeting the polo-box domain of polo-like kinase 1.
    Li Z; Zhang Z; Chen Y; Tang S; Lin T; Huang J; Li B; Jiang C
    Bioorg Chem; 2019 Apr; 85():534-540. PubMed ID: 30807896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.